Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

WuXi’s New Unit Joins Race For Drug Innovation In China

This article was originally published in The Pink Sheet Daily

Executive Summary

WuXi is opening up its service platform, manufacturing capacity and pockets, aiming to develop global biotech innovations in China faster and cost-effectively. The strategy may draw on a template of a joint venture with MedImmune and a contract manufacturing deal for Ambrx already in place.

You may also be interested in...



Low Sinopharm Protection In Elderly Casts New Doubt On Chinese COVID-19 Vaccines

A new study in over 400 people reignites fears about the apparent low efficacy of Chinese COVID-19 vaccines, especially among the elderly, and adding to the debate around the need for booster shots.

As US, China Intensify Cybersecurity Crackdown, Companies Urged To Be Conservative

The latest developments around data security and protection signal the need for rigorous implementation of procedures and potential significant cost increases for pharma and other companies operating in China.

Fosun-BioNTech mRNA Vaccine Nears China Green Light

There is talk about offering booster shots to people who have already been fully vaccinated against COVID-19 in China and it’s increasingly clear that the mRNA vaccine from BioNTech/Fosun nearing approval could be the answer. Meanwhile, some Asian countries are turning away from Chinese coronavirus vaccines. 

Topics

Related Companies

UsernamePublicRestriction

Register

PS077386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel